Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine ...
Hosted on MSN12d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
(RTTNews) - BriaCell Therapeutics Corp. (BCTX, BCTXW, BCT.TO) announced the pricing of a public offering of 762,500 common shares at a public offering price of $4.00 per share. The company expects ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell” or the "Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today ...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp ... sell common shares in a best-efforts public offering. The offering is subject ...
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq ... that it intends to offer to sell common shares in a best-efforts public offering ...
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
In addition, Maze Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the initial public offering price, less underwriting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback